Generic Name: cladribine
Dosage Form: Tablets
Company: Merck
FDA Approved: March 2019
Specific Treatments: relapsing multiple sclerosis
Rated: N/A
Mavenclad is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsingremitting disease and active secondary progressive disease, in adults. Because of its safety profile, Mavenclad is generally used in people who have tried another MS medicine that they could not tolerate or that has not worked well enough.
Recommended Dosage
The recommended cumulative dosage of MAVENCLAD is 3.5 mg per kg body weight administered orally and divided into 2 yearly treatment courses, Each treatment course is divided into 2 treatment cycles.
Administer the cycle dosage as 1 or 2 tablets once daily over 4 or 5 consecutive days Do not administer more than 2 tablets daily.
Following the administration of 2 treatment courses, do not administer additional MAVENCLAD treatment during the next 2 years. Treatment during these 2 years may further increase the risk of malignancy. The safety and efficacy of reinitiating MAVENCLAD more than 2 years after completing 2 treatment courses has not been studied.
MAVENCLAD tablets are taken orally, with water, and swallowed whole without chewing. MAVENCLAD can be taken with or without food.
No comments:
Post a Comment